NeoGraph Analytics
BiotechnologyGlobal2026 – 2032

Phage Therapy Market Size, Share & Forecast 2026-2032

No approved phage therapeutic exists in the US, EU or UK, and 124 trials are registered. Why published forecasts spread 33x and what the register rules out.

Revenue, 2026

$66.5M

Forecast, 2032

$167.9M

CAGR, 2026-2032

16.7%

Report Coverage

Global

Code: phage-therapy-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Published estimates of the phage therapy market run from $38.6 million to $1,280.9 million - a 33.2x spread, the widest we have measured in any market in this corpus. The explanation is not a definition subtlety. It is that most of these figures are describing a market that does not yet exist.

There is no approved bacteriophage therapeutic for human use in the United States, the European Union or the United Kingdom. The UK regulator's November 2025 guidance says so explicitly. In the US, phage reaches patients only through investigational new drug applications and expanded access; in Belgium, through magistral pharmacy preparation. The most advanced Western registrational programme, Armata's AP-SA02, received Qualified Infectious Disease Product status in February 2026 and Fast Track in May 2026 and planned to begin Phase 3 in the second half of that year. Designations are not approvals, and approved-product revenue for human phage therapy is therefore approximately zero.

That makes the high published figures testable. ClinicalTrials.gov lists 124 registered studies with a bacteriophage intervention, of which 22 are recruiting and 9 are Phase 3. Divide $1,280.9 million by 124 and you get $10.3 million per registered study - impossible as revenue, since nothing is approved, and not credible as sponsor R&D spend across a population that is mostly closed, terminated or not yet open and mostly early-phase academic work. The low cluster implies $311,000 per study, which is what a grant-funded field looks like. The likeliest reading of the high cluster is that it counts phage products approved for food safety and biocontrol - ListShield was cleared by the FDA as a food additive in 2006 under 21 CFR 172.785 - which is a genuine market and not the one a reader searching for phage therapy is asking about.

The figures published here, $66.5 million in 2026 to $167.93 million by 2032, should be read for what they are: option value on a Phase 3 result that has not been read out.

02

Key Highlights

1

No human phage therapeutic holds a marketing authorisation in the US, EU or UK, so approved-product revenue is approximately zero

2

Published estimates spread 33.2x, from $38.6 million to $1,280.9 million

3

ClinicalTrials.gov lists 124 registered bacteriophage studies, with 22 recruiting and 9 Phase 3, as of 16 October 2026

4

The high published estimate implies $10.3 million per registered study, which works as neither revenue nor research spend

5

The low cluster implies $311,000 per registered study, consistent with a grant-funded field

6

Phage approved for food safety - ListShield, cleared as a food additive in 2006 - is the most plausible subject of the high estimates

7

Armata's AP-SA02 planned to start Phase 3 in the second half of 2026 after QIDP and Fast Track designations

03

Market Overview

Market Context

Phage therapy is older than antibiotics and commercially younger. Bacteriophages were used clinically in the 1920s and 1930s, were displaced in the West by small-molecule antibiotics, and continued in the Soviet sphere - the Eliava Institute in Georgia has the longest continuous practice in the world. The renewed Western interest is a consequence of antimicrobial resistance rather than of new biology. What has not been solved is the regulatory fit. A phage is specific to a narrow range of bacterial strains, which is clinically attractive and commercially awkward: effective treatment usually requires matching a preparation to the patient's own isolate, while a marketing authorisation describes a product of fixed composition. Phage also replicates at the site of infection, so dose-response does not behave the way a small molecule's does, and bacteria acquire resistance to phage, so a cocktail's composition has a shelf life. Each of these is a reason registrational trials have been slow to start rather than a reason they cannot succeed. The interim arrangements shape what is observable. Belgium's magistral framework, hospital exemptions elsewhere and the US expanded-access route all allow patients to be treated without a product ever being authorised or a sale ever being recorded in a way an analyst can count. So the register of trials is the only public denominator available, and the number that matters most about this market - how many patients have been treated and with what result - is not centrally recorded anywhere.

There is no approved bacteriophage therapeutic for human use in the United States, the European Union or the United Kingdom. Access runs through investigational and expanded-access routes, and ClinicalTrials.gov lists 124 registered studies, 9 of them Phase 3 and 22 currently recruiting. Published estimates of this market spread 33.2x, from $38.6 million to $1,280.9 million, and the per-trial arithmetic rules out the high cluster as a description of human phage therapy. On the most current published base this is a $66.5 million market in 2026 reaching $167.93 million by 2032 at 16.7% - option value, not revenue.

Market Stage

Emerging

Adoption Level

Pre-approval; compassionate use and magistral preparation only

Key Trends

No marketing authorisation exists for a human phage therapeutic in the US, EU or UK, so approved-product revenue is approximately zeroPublished estimates spread 33.2x ($38.6 million to $1,280.9 million), the widest spread we have measured in any market in this corpusClinicalTrials.gov lists 124 registered bacteriophage studies, of which only 22 are recruiting and 9 are Phase 3, as of October 2026Dividing the high published estimate by the register gives $10.3 million per registered study, which is implausible as either revenue or R&D spendPhage products approved as food additives and biocontrol agents - ListShield was cleared by the FDA in 2006 under 21 CFR 172.785 - are a real market and are the most likely explanation for the high clusterThe most advanced Western therapeutic programme, Armata's AP-SA02, received Fast Track in May 2026 with a Phase 3 planned to start in the second half of 2026
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 16.7%

Base Year (2026)

$66.5M

Forecast (2032)

$167.9M

CAGR (2026-2032)

16.7%

Market size by year, 2026-2032, in USD Million.
YearMarket size ($ Million)
2026Base year$66.50M
2027$77.59M
2028$90.54M
2029$105.66M
2030$123.31M
2031$143.90M
2032$167.93M
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

The curve starts at $66.5 million for 2026, the most current published base-year figure, and compounds at the same publisher's 16.7% rate to $167.93 million by 2032. Intermediate years are interpolation on that rate. This series was chosen because its base year is the current year and because it sits inside the only cluster that the per-trial arithmetic supports; the $1.27-1.28 billion cluster is cited in this report as a contrast and is explicitly ruled out, not carried. The honest reading of any number on this chart is that it is a valuation, not a measurement. With no approved product in the US, EU or UK, the entire forecast depends on a binary event: whether a registrational trial succeeds and an authorisation follows. Nine Phase 3 studies have ever been registered in this field, and the most advanced Western programme planned to begin its Phase 3 in late 2026. If AP-SA02 or a comparable programme reads out positively and is approved, the realised market will not follow a 16.7% curve from $66.5 million - it will step. If the readouts are negative, the curve has no revenue underneath it at all. A 16.7% smooth compound rate is therefore the wrong shape for what will actually happen, and we publish it only because it is what the most defensible public source publishes. Readers should treat the 2032 figure as a probability-weighted placeholder and track the Phase 3 register instead.

05

Market Dynamics

  • Antimicrobial resistance creating demand for mechanisms that do not depend on small-molecule antibiotic classes
  • Phage specificity and self-limiting replication, which allow targeted treatment of a single pathogen species
  • Regulatory movement toward workable individual-patient access, including updated FDA expanded-access guidance
  • Designation incentives in practice: Qualified Infectious Disease Product status and Fast Track granted to AP-SA02 in 2026
  • Established non-therapeutic phage markets in food safety and biocontrol, which have built manufacturing and regulatory precedent
06

Market Segmentation

By Type

  • Natural phage monotherapy
  • Defined phage cocktails
  • Engineered and synthetic phage
  • Phage-derived enzymes (lysins)
  • Phage-antibiotic combination regimens

By End User

  • Academic medical centres running investigational protocols
  • Specialist antimicrobial resistance referral centres
  • Compounding and magistral preparation pharmacies
  • Biotechnology sponsors and contract manufacturers

By Application

  • Bacteraemia and endocarditis
  • Prosthetic joint and device-associated infection
  • Respiratory infection in cystic fibrosis and bronchiectasis
  • Urinary tract infection
  • Chronic wound and diabetic foot infection
07

Competitive Landscape

A

Armata Pharmaceuticals

United States

Most advanced Western registrational programme

Lead candidate AP-SA02 for Staphylococcus aureus bacteraemia received Qualified Infectious Disease Product status in February 2026 and Fast Track designation in May 2026, with a Phase 3 superiority protocol submitted to the FDA and the trial planned to begin in the second half of 2026. No approved product and therefore no product revenue.

B

BiomX

Israel and United States

Clinical-stage, targeted indications

Develops phage cocktails for defined indications including cystic fibrosis respiratory infection and diabetic foot osteomyelitis. Clinical stage only; no marketing authorisation and no product revenue.

I

Intralytix

United States

The only segment with approved, revenue-generating phage products

Holds FDA clearance for ListShield as a food additive for ready-to-eat foods, approved 18 August 2006 under 21 CFR 172.785 and separately registered by the EPA as a microbial pesticide, plus EcoShield, SalmoFresh and CampyShield for food-safety use. This non-therapeutic business is the most plausible explanation for published market sizes near $1.28 billion, and it is not human phage therapy.

E

Eliava Institute

Georgia

Longest continuous clinical practice

Operates the longest-running phage therapy practice in the world and supplies preparations used by patients who travel for treatment. Operating outside US, EU and UK marketing authorisation frameworks, so its activity does not appear in any authorisation register and its volume is not publicly quantified.

A

Adaptive Phage Therapeutics

United States

Phage-bank model, expanded access

Built a phage-bank approach intended to match preparations to a patient's isolate, and received an FDA expanded-access IND in 2020 for secondary bacterial infections in COVID-19 patients. An expanded-access clearance is not a marketing authorisation.

08

Regulatory Landscape

FDA investigational new drug application, the only route by which phage preparations are legally administered in the United StatesFDA expanded access (compassionate use) pathway, including updated guidance for individual-patient use, which is how most US phage treatment has occurredQualified Infectious Disease Product designation and Fast Track designation under the GAIN provisions, both granted to AP-SA02 in 2026 - incentives, not approvalsUK MHRA guidance of November 2025, which states there are no marketing authorisations for bacteriophage medicinal products in the UKBelgian magistral preparation framework, under which phage preparations are compounded against a prescription rather than authorised as productsFDA food additive regulation 21 CFR 172.785 and EPA microbial pesticide registration, the pathways under which phage products are already approved for non-therapeutic use
09

Research Methodology

Primary research

  • No primary interviews were conducted for this edition. The report rests on public clinical trial registers, regulatory statements and published third-party estimates, and is labelled as such rather than implying fieldwork that did not occur.

Secondary research

  • ClinicalTrials.gov API v2, intervention 'bacteriophage': 124 registered studies, 22 recruiting, 9 Phase 3, all retrieved 16 October 2026
  • Exploration Publishing review (2026) on phage therapy regulation and FDA IND and expanded-access mechanisms
  • UK MHRA guidance, November 2025: no marketing authorisations for bacteriophage medicinal products in the UK
  • Armata Pharmaceuticals announcements (2026): AP-SA02 Phase 3 protocol submitted, QIDP granted February 2026, Fast Track granted May 2026
  • Intralytix product documentation: ListShield FDA food additive approval of 18 August 2006 under 21 CFR 172.785, EPA microbial pesticide registration, CampyShield GRAS notice GRN 966 (2020)
  • Published market estimates from QYResearch (2024), Roots Analysis (2026), Verified Market Research via GII (2025) and Coherent Market Insights (2024)

Validation: The headline figures are Roots Analysis's published 2026 base of $66.5 million and its published 16.7% CAGR; intermediate years are interpolation on that rate, not separate observations. That base was chosen because its base year is the current year and because it falls inside the only cluster the grounding arithmetic supports. The grounding check divides the high published estimate by a countable register: $1,280.9 million over 124 bacteriophage studies registered on ClinicalTrials.gov is $10.3 million per registered study, against a population in which only 22 studies are recruiting and only 9 have ever been Phase 3. That cannot be product revenue, because no human phage therapeutic holds a marketing authorisation in the US, EU or UK; and it is not credible as sponsor R&D spend either. The low cluster implies $311,000 per registered study, which is consistent with a field funded largely by academic and government grants. The arithmetic therefore rules out the high cluster as a description of human phage therapy - most likely it counts phage products approved for food safety and biocontrol instead. This is a plausibility test, not a market estimate, and the published figures it supports should be read as option value on an unread Phase 3 result rather than as revenue.

10

Strategic Takeaways

Treat every phage therapy market size as option value

no human therapeutic is approved in the US, EU or UK, so there is no revenue underneath the figures

Reject the $1.27-1.28 billion cluster for this market - it implies $10.3 million per registered trial and most likely counts food-safety phage instead

Track the register rather than the forecast

124 studies, 22 recruiting and 9 ever in Phase 3 is the real state of the field

The binding problem is regulatory fit, not biology - fixed-composition authorisation versus isolate-matched treatment

Expect a step change on a positive Phase 3 readout, not the smooth 16.7% curve any published series implies

11

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.